查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595629

前列腺癌診斷市場：按測試類型、年齡層和最終用戶 - 2025-2030 年全球預測

Prostate Cancer Diagnostics Market by Test Type (Confirmatory Tests, Preliminary Tests), Age Group (Age 55-75, Age <55, Age>75), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年前列腺癌診斷市場價值為12.7億美元，預計到2024年將達到14.5億美元，複合年成長率為14.20%，到2030年將達到32.3億美元。

前列腺癌診斷市場包括用於識別和監測前列腺癌患者的各種測試和技術。這包括 PSA（前列腺特異性抗原）測試和切片檢查等傳統方法，以及 MRI 和基因組測試等先進程序。從攝護腺癌的盛行率來看，尤其是在人口老化的人群中，對有效診斷工具的需求顯而易見，而準確的診斷對於有效的治療和管理至關重要。治療方法多種多樣，包括早期發現、疾病進展監測和治療效果評估。最終使用者包括醫院、診斷實驗室、癌症治療中心等。

主要市場統計
基準年[2023] 12.7億美元
預測年份 [2024] 14.5億美元
預測年份 [2030] 32.3億美元
複合年成長率（%） 14.20%

市場成長的主要驅動力是前列腺癌盛行率的增加、技術進步以及對該疾病的認知不斷提高。個人化醫療和生物標記測試提供了重要的機會，重點是提高診斷準確性和針對患者的治療計劃。將人工智慧整合到診斷工具中也有希望，有可能提高檢測率並減少解釋時間。為提高診斷工具的敏感度和特異性而進行的研發投資可能會為產業參與者帶來顯著的好處。值得注意的是，新興市場的醫療保健基礎設施正在開發中，並且存在尚未開發的開拓潛力。

然而，挑戰依然存在，例如先進診斷技術的高成本以及低度開發地區缺乏足夠的醫療基礎設施。此外，標準診斷方法可能會產生誤報，可能導致不必要的治療，這突顯出需要更精確和可靠的測試。監管障礙和冗長的核准流程也對市場進入和創新造成了障礙。

專注於非侵入性測試方法的創新，例如液態切片和多參數成像，代表了有希望的研究途徑。此外，巨量資料和機器學習用於分析患者資料並執行模式識別，這提供了有助於早期診斷和個人化治療策略的見解，進一步推動市場成長。為了利用這些機會，公司必須投資於技術進步和策略夥伴關係，以增加市場佔有率和影響力。

市場動態：快速發展的前列腺癌診斷市場的關鍵市場洞察

供需的動態交互作用正在改變前列腺癌診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 人口老化加劇和前列腺癌盛行率增加
    • 癌症診斷技術的進步和政府不斷意識提升的舉措
  • 市場限制因素
    • 嚴格的監管和不斷上升的診斷成本
  • 市場機會
    • 基因組學和蛋白​​質組學的製藥創新和進步
    • 準確檢測前列腺癌的影像學研究和進展
  • 市場挑戰
    • 臨床試驗成功率低

波特五力：駕馭前列腺癌診斷市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對前列腺癌診斷市場的影響

外部宏觀環境因素在塑造前列腺癌診斷市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解前列腺癌診斷藥物市場的競爭狀況

前列腺癌診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 在前列腺癌診斷市場的定位矩陣供應商績效評估

FPNV定位矩陣是評估前列腺癌診斷市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪前列腺癌診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對前列腺癌診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口老化加劇和前列腺癌發生率增加
      • 加強政府努力改進癌症診斷技術並提高人們對癌症的認知
    • 抑制因素
      • 嚴格的法規和高昂的診斷成本
    • 機會
      • 基因組學和蛋白​​質組學的製藥創新和進步
      • 準確檢測前列腺癌的影像學研究和進展
    • 任務
      • 臨床試驗成功率低
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按測試類型分類的前列腺癌診斷藥物市場

  • 確認測試
    • 切片檢查
    • PCA3測試
    • 經直腸超音波檢查
  • 初步測試

第7章前列腺癌診斷藥物市場：依年齡層

  • 年齡55-75歲
  • 年齡55歲以下
  • 年齡>75

第8章前列腺癌診斷市場：依最終用戶分類

  • 癌症研究組織
  • 醫院相關實驗室
  • 獨立診斷實驗室

第9章美洲前列腺癌診斷市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區攝護腺癌診斷藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲的攝護腺癌診斷市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AdvaCare Pharma
  • bioMerieux SA
  • Eurolyser Diagnostica
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche AG
  • Hologic, Inc.
  • Koninklijke Philips NV
  • mdxhealth BV
  • Myriad Genetics, Inc.
  • OPKO Health, Inc.
  • Prostatype Genomics AB
  • Proteomedix AG
  • Siemens Healthineers AG
Product Code: MRR-A339DAEFAC09

The Prostate Cancer Diagnostics Market was valued at USD 1.27 billion in 2023, expected to reach USD 1.45 billion in 2024, and is projected to grow at a CAGR of 14.20%, to USD 3.23 billion by 2030.

The prostate cancer diagnostics market encompasses a range of tests and technologies used to identify and monitor prostate cancer in patients. This involves traditional methods like PSA (prostate-specific antigen) tests and biopsies, as well as advanced procedures including MRI and genomic testing. The necessity of efficient diagnostic tools is evident due to the prevalence of prostate cancer, particularly in aging populations, making accurate diagnosis crucial for effective treatment and management. Applications extend into early detection, monitoring disease progression, and evaluating treatment efficacy. End-users include hospitals, diagnostic laboratories, and cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 1.27 billion
Estimated Year [2024] USD 1.45 billion
Forecast Year [2030] USD 3.23 billion
CAGR (%) 14.20%

Market growth is primarily driven by increasing incidences of prostate cancer, technological advancements, and rising awareness about the disease. Personalized medicine and biomarker tests present significant opportunities, focusing on enhancing diagnostic accuracy and patient-specific treatment plans. The integration of artificial intelligence in diagnostic tools also shows promise, potentially improving detection rates and reducing interpretation time. Investment in research and development to enhance the sensitivity and specificity of diagnostic tools will likely yield significant gains for industry players. Notably, emerging markets with developing healthcare infrastructures offer untapped potential for expansion.

However, challenges persist, such as high costs associated with advanced diagnostic technologies and a lack of adequate healthcare infrastructure in underdeveloped regions. Additionally, the potential for false positives in standard diagnostic methods could lead to unnecessary procedures, emphasizing a need for more precise and reliable tests. Regulatory hurdles and the lengthy approval processes also pose barriers to market entrants and innovations.

Innovations focusing on non-invasive testing methods, such as liquid biopsies and multi-parametric imaging, represent promising avenues for research. Moreover, the use of big data and machine learning to analyze patient data for pattern recognition will provide insights contributing to early diagnosis and personalized treatment strategies, further driving market growth. To leverage these opportunities, companies should invest in technology advancements and strategic partnerships to increase their market share and influence.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Prostate Cancer Diagnostics Market

The Prostate Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising aging population and increasing prevalence rate of prostate cancer
    • Growing government's initiatives for advancement in technology in diagnosis and creating awareness regarding cancer
  • Market Restraints
    • Stringent regulations and high cost of diagnosis
  • Market Opportunities
    • Innovation in drugs and developments in genomics and proteomics
    • Imaging research and advancements for accurate detection of prostate cancer
  • Market Challenges
    • Low success rate of clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the Prostate Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Prostate Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Prostate Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Prostate Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Prostate Cancer Diagnostics Market

A detailed market share analysis in the Prostate Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Prostate Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Prostate Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Prostate Cancer Diagnostics Market

A strategic analysis of the Prostate Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Prostate Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include AdvaCare Pharma, bioMerieux SA, Eurolyser Diagnostica, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Hologic, Inc., Koninklijke Philips N.V., mdxhealth BV, Myriad Genetics, Inc., OPKO Health, Inc., Prostatype Genomics AB, Proteomedix AG, and Siemens Healthineers AG.

Market Segmentation & Coverage

This research report categorizes the Prostate Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test Type, market is studied across Confirmatory Tests and Preliminary Tests. The Confirmatory Tests is further studied across Biopsy, PCA3 Tests, and Trans-Rectal Ultrasound.
  • Based on Age Group, market is studied across Age 55-75, Age 75.
  • Based on End-User, market is studied across Cancer Research Institutes, Hospital Associated Laboratories, and Independent Diagnostic Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising aging population and increasing prevalence rate of prostate cancer
      • 5.1.1.2. Growing government's initiatives for advancement in technology in diagnosis and creating awareness regarding cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulations and high cost of diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovation in drugs and developments in genomics and proteomics
      • 5.1.3.2. Imaging research and advancements for accurate detection of prostate cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Low success rate of clinical trials
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Prostate Cancer Diagnostics Market, by Test Type

  • 6.1. Introduction
  • 6.2. Confirmatory Tests
    • 6.2.1. Biopsy
    • 6.2.2. PCA3 Tests
    • 6.2.3. Trans-Rectal Ultrasound
  • 6.3. Preliminary Tests

7. Prostate Cancer Diagnostics Market, by Age Group

  • 7.1. Introduction
  • 7.2. Age 55-75
  • 7.3. Age < 55
  • 7.4. Age > 75

8. Prostate Cancer Diagnostics Market, by End-User

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Hospital Associated Laboratories
  • 8.4. Independent Diagnostic Laboratories

9. Americas Prostate Cancer Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Prostate Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Prostate Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AdvaCare Pharma
  • 2. bioMerieux SA
  • 3. Eurolyser Diagnostica
  • 4. Exact Sciences Corporation
  • 5. F. Hoffmann-La Roche AG
  • 6. Hologic, Inc.
  • 7. Koninklijke Philips N.V.
  • 8. mdxhealth BV
  • 9. Myriad Genetics, Inc.
  • 10. OPKO Health, Inc.
  • 11. Prostatype Genomics AB
  • 12. Proteomedix AG
  • 13. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. PROSTATE CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PROSTATE CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PROSTATE CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PCA3 TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TRANS-RECTAL ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY PRELIMINARY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE 55-75, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE <55, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE>75, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITAL ASSOCIATED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY INDEPENDENT DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY CONFIRMATORY TESTS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM PROSTATE CANCER DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. PROSTATE CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. PROSTATE CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023